DNA mismatch repair and microsatellite instability in colorectal tumors: an observational study in the Veterans Affairs Health Care System-Reference-Cited by-同舟云学术

DNA mismatch repair and microsatellite instability in colorectal tumors: an observational study in the Veterans Affairs Health Care System

Published:2022-02 Issue:6 Volume:18 Page:649-660
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Waller Justin¹,Gu Lin¹²,De Hoedt Amanda M¹,Freedland Stephen J¹³,Wang Tongtong⁴,Amonkar Mayur⁵,Aurora-Garg Deepti⁶,Liaw Kai-Li⁴,Wehn Amy⁶,Klaassen Zachary¹⁷⁸

Affiliation:

1. Durham Veterans Affairs Health Care System, Durham, NC 27705, USA

2. Duke Cancer Institute, Biostatistics Shared Resource, Durham, NC 27710, USA

3. Center for Integrated Research on Cancer & Lifestyle, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

4. Epidemiology, Merck & Co., Inc., Kenilworth, NJ 07033, USA

5. Center for Observational & Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ 07033, USA

6. Research Science, Merck & Co., Inc., Kenilworth, NJ 07033, USA

7. Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA

8. Department of Surgery, Division of Urology, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA

Abstract

Background: Challenges in identifying microsatellite instability (MSI)/mismatch repair (MMR)-tested colorectal carcinoma (CRC) patients in electronic health records have led to gaps in the understanding of MSI-high/deficient mismatch repair prevalence. Methods: An algorithm to identify MSI-/MMR-tested Veterans Affairs patients was developed and an observational study of adult CRC patients with MSI/MMR testing from 2010 to 2018 was undertaken. Results: An optimized model to identify MSI-/MMR-tested patients yielded high positive predictive value (89.0%) and specificity (97.8%). The authors observed MSI-high/deficient mismatch repair CRC in 54 of 291 patients (18.6%); highest frequencies were observed in stages II (25.9%) and III (22.6%) and lowest in stage IV (5.8%). Conclusions: In this real-world study, the authors proposed a novel method of identifying MSI-/MMR-tested patients. Further validation and refinement of this model, and study in a larger CRC cohort, is warranted.

Funder

Merck Sharp & Dohme

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-0874

Reference42 articles.

1. Clinical Relevance of Microsatellite Instability in Colorectal Cancer

2. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

3. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019

4. Identifying mismatch repair‐deficient colon cancer: near‐perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population‐based series

5. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain;Clinical and Translational Oncology;2023-08-31

2. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain;CLIN TRANSL ONCOL;2023